NEW YORK (GenomeWeb News) – Ventana Medical Systems and Boehringer Ingelheim announced today that they will collaborate on the development of companion diagnostic products for cancer drugs in the German drug firm's pipeline.
Ventana plans to utilize its immunohistochemistry technology platform and its experience in companion diagnostic development and premarket approval submissions to support Boehringer Ingelheim's personalized medicine strategies for cancer drug development, the firms said. The partners didn't name specific drug candidates or types of cancers that would be targeted by the collaboration.
Further terms of the alliance also were not disclosed.